[{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Native Type Ii Collagen","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Chondroitin Sulphate","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Large Molecule","year":"2020","type":"Inapplicable","leadProduct":"Harpagophytum Procumbens Extract","moa":"||Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"ByHealth","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Large Molecule","year":"2022","type":"Partnership","leadProduct":"Undenatured Type II Collagen","moa":"Undisclosed","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ ByHealth","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ ByHealth"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"GERMANY","productType":"Other Small Molecule","year":"2020","type":"Agreement","leadProduct":"Chondroitin Sulfate Sodium","moa":"||ELA2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Bioiberica","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Bioiberica"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Apsen","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Apsen","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Apsen"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"SPAIN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Chondroitin Sulfate Sodium","moa":"ELA2","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Dermatology","graph2":"Preclinical","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"HA Matrix","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Inapplicable"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2020","type":"Partnership","leadProduct":"Hyaluronic Acid","moa":"||Collagen synthesis","graph1":"Musculoskeletal","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Bioiberica","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Bioiberica"},{"orgOrder":0,"company":"Bioiberica","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Bioiberica","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bioiberica \/ Inapplicable","highestDevelopmentStatusID":"1","companyTruncated":"Bioiberica \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Bioiberica

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : HA Matrix

                          Therapeutic Area : Dermatology

                          Study Phase : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Dietary Supplement

                          Upfront Cash : Inapplicable

                          April 14, 2023

                          Lead Product(s) : HA Matrix

                          Therapeutic Area : Dermatology

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bioiberica Company Banner

                          02

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Study Phase : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Aim is to develop innovative multifunctional biomaterials to heal wounds using affordable EU-based manufacturing technologies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Inapplicable

                          January 18, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bioiberica Company Banner

                          03

                          Lead Product(s) : Undenatured Type II Collagen

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Approved FDF

                          Sponsor : ByHealth

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : By partnering with Bioiberica, ByHealth aims to capitalise on the untapped potential of new product development with native type II collagen and respond to the growing number of consumers looking to support their mobility with effective, convenient produ...

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Undisclosed

                          November 03, 2022

                          Lead Product(s) : Undenatured Type II Collagen

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : ByHealth

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Bioiberica Company Banner

                          04

                          Lead Product(s) : Hyaluronic Acid,Collagen,Dermatan Sulfate

                          Therapeutic Area : Dermatology

                          Study Phase : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : New pre-clinical study showed that Dermial® hyaluronic acid matrix ingredient increased type I collagen production by almost half – an observation not seen with standard hyaluronic acid from fermentation or extraction origin.

                          Product Name : Dermial

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 25, 2022

                          Lead Product(s) : Hyaluronic Acid,Collagen,Dermatan Sulfate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bioiberica Company Banner

                          05

                          Lead Product(s) : Native Type Ii Collagen

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 16, 2022

                          Lead Product(s) : Native Type Ii Collagen

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Undisclosed

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bioiberica Company Banner

                          06

                          Lead Product(s) : Chondroitin Sulfate Sodium

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Bioiberica’s native (undenatured) type II collagen, Collavant® n2 (previously b2-Cool®) and the addition of Tendaxion® - a new brand for its tendon health ingredient.

                          Product Name : CSbioactive

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 07, 2021

                          Lead Product(s) : Chondroitin Sulfate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bioiberica Company Banner

                          07

                          Lead Product(s) : Hyaluronic Acid,Type II Collagen

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Approved FDF

                          Sponsor : Apsen

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Details : Apsen’s Motilex HA combines two leading ingredients, b-2Cool native type II collagen and Mobilee, patented ingredient that synergistically combines a high concentration of hyaluronic acid with polysaccharides and collagen, to effectively maintain joint...

                          Product Name : Motilex HA

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          April 26, 2021

                          Lead Product(s) : Hyaluronic Acid,Type II Collagen

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Apsen

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          Bioiberica Company Banner

                          08

                          Details : Under the terms of the agreement, Bayer Animal Health will distribute and market selected products from Bioiberica´s Companion Animal Health portfolio in eight countries.

                          Product Name : Condrovet

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 06, 2020

                          Lead Product(s) : Chondroitin Sulfate Sodium,Glucosamine,Hyaluronic Acid

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Recipient : Bayer AG

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          Bioiberica Company Banner

                          09

                          Lead Product(s) : Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : B-2Cool (Bioiberica’s native type II collagen) is an innovative ingredient, has been shown in four scientific studies to help maintain good joint health at a very low daily dose.

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          July 15, 2020

                          Lead Product(s) : Undenatured Type II Collagen,Harpagophytum Procumbens Extract,Hyaluronic Acid

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bioiberica Company Banner

                          10

                          Lead Product(s) : Undenatured Type II Collagen,Chondroitin Sulfate Sodium,Hyaluronic Acid

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : The study, conducted in a rabbit model of osteoarthritis, set out to evaluate the effects of b-2Cool native type II collagen in combination with CS b-Bioactive chondroitin sulphate, glucosamine hydrochloride and Mobilee® which is a rooster comb extract ...

                          Product Name : Undisclosed

                          Product Type : Other Large Molecule

                          Upfront Cash : Inapplicable

                          July 09, 2020

                          Lead Product(s) : Undenatured Type II Collagen,Chondroitin Sulfate Sodium,Hyaluronic Acid

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Bioiberica Company Banner